Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected

This article was originally published in The Pink Sheet Daily

Executive Summary

Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.

You may also be interested in...



EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension

Europe's scientific advisory committee, the CHMP, gives positive opinions on apixaban and Viropharma's Cinryze, but doesn't want Vectibix's indications extended.

EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension

Europe's scientific advisory committee, the CHMP, gives positive opinions on apixaban and Viropharma's Cinryze, but doesn't want Vectibix's indications extended.

The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies

Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel